Clinical effect of montelukast sodium combined with interferon α1b in treatment of pediatric asthmatic bronchitis

Abstract

Objective To study clinical effect of montelukast sodium combined with interferon α1b in treatment of pediatric asthmatic bronchitis (AB). Methods From April 2013 to April 2014, a total of 80 cases of children with AB who hospitalized in the Eighth Hospital of Wuhan City were admitted as research objects. According to their odd and even number of admission, they were randomly divided into experimental group (n=40) and control group (n=40). All the patients were in accordance with the clinical diagnostic criteria of AB, and the patients who had the history of drug allergy, liver and renal insufficiency were excluded. In experimental group, the patients were treated with montelukast sodium combined with interferon α1b, while control group was treated with routine method. The treatment effective rate, satisfaction degree and hospitalization time, etc. between two groups were statistically analyzed. The procedure that this study followed met the ethical standards made by Institutional Review Board of the Eighth Hospital of Wuhan City in Hebei Province and approved by the committee. Grouping had the consent of guardians of study subjects and clinical study letter of consent was signed. The differences in age, gender ratio, course of disease and other general clinical data of the patients between two groups were not statistically significant (P>0.05). Results The effective rate and the treatment satisfaction of guardians of study subjects in experimental group were 95.0% and 97.5% which were significantly better than 80.0% and 77.5% of control group, there were significant differences between two groups(χ2=4.114, 7.314; P 0.05) . Conclusions At present, the incidence rate of AB in children is high, and the treatment effect of strategy of montelukast sodium combined with interferon α1b is ideal. Whether montelukast sodium combined with interferon α1b in treating pediatric AB is worthy of clinical promotion and application or not, it still needs to be further confirmed by randomized controlled trials of multiple centers and large samples. Key words: Montelukast sodium; Interferon α1b; Drug therapy, combination; Bronchitis; Asthma; Treatment outcomes